SEC Comment Letter for ABBOTT LABORATORIES (ABT) — Nov 16, 2017
ABBOTT LABORATORIES
Date: Nov. 16, 2017 · CIK: 0000001800 · Accession: 0000000000-17-040639
AI Filing Summary & Sentiment
Referenced dates: November 7, 2017
Letter
Re: Abbott Laboratories Form 10 -K for the Fiscal Year Ended December 31, 2016 Filed February 17, 2017 File No. 1-02189 Dear Mr. White: We refer you to our comment letter dated November 7, 2017, regarding business contacts with Syria. We have completed our review of this subject matter. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
November 16, 2017
Via E -mail Miles D. White Chairman of the Board and Chief Executive Officer Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064 -6400
Sincerely,
/s/ Cecilia Blye
Show Raw Text
November 16, 2017
Via E -mail
Miles D. White
Chairman of the Board and Chief Executive Officer
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064 -6400
Re: Abbott Laboratories
Form 10 -K for the Fiscal Year Ended December 31, 2016
Filed February 17, 2017
File No. 1-02189
Dear Mr. White:
We refer you to our comment letter dated November 7, 2017, regarding business contacts
with Syria. We have completed our review of this subject matter. We remind you that the
company and its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
/s/ Cecilia Blye
Cecilia Blye, Chief
Office of Global Security Risk
cc: Suzanne Hayes
Assistant Director
Division of Corporation Finance